Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market: By Product Type, By Target Population, By Clinical Trial Phase and Geography

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Vaccines, and Monoclonal Antibodies), By Target Population (Infants, Older Adults, and Pregnant Women), By Clinical Trial Phase (Phase I, Phase II, and Phase III) and Region

checked icon arrow_drop_down
checked icon Single User License $4400
checked icon Multiple User License $6600
checked icon Corporate User License $8900

Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market is poised to grow at a CAGR of 27.1% from 2024 to 2030. RSV is a major cause of lower respiratory tract infections, particularly severe in infants, older adults, and immunocompromised individuals. Globally, RSV causes an estimated 33 million cases of acute lower respiratory infection in children under 5 years annually, resulting in more than 3 million hospitalizations and about 60,000 in-hospital deaths in children under 5 years. The increasing recognition of RSV's significant health and economic burden drives the market for vaccines and antibodies. Additionally, the COVID-19 pandemic has heightened awareness about respiratory viruses, accelerating research and development in this field.

Technological advancements, including the application of mRNA technology and structure-based vaccine design, contribute to market growth by improving vaccine efficacy and production efficiency. Recent breakthroughs in understanding RSV's molecular structure and immune responses have reinvigorated the field after previous setbacks. However, challenges such as the virus's ability to evade immune responses and the need for different approaches for various age groups may impact market dynamics. Stringent regulatory requirements, given past vaccine-enhanced disease incidents, also influence development timelines and market entry. North America held the largest market share in 2023 and is expected to maintain its dominance in the forecast period, driven by robust research infrastructure and high healthcare expenditure.

Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market Key Develpments:

In August 2023, Pfizer received additional FDA approval for ABRYSVO, their RSV vaccine. This development:

  • Expands the use of ABRYSVO to pregnant individuals
  • Aims to prevent RSV in infants through maternal immunization
  • Demonstrated 81.8% efficacy against severe medically attended lower respiratory tract illness in infants up to 6 months of age
  • This represents a significant advancement in protecting newborns against RSV

In July 2023, Pfizer received FDA approval for ABRYSVO, their RSV vaccine for older adults. This development:

  • Introduces a new RSV vaccine option for the older adult population
  • Demonstrated 66.7% efficacy against RSV-associated lower respiratory tract illness with two or more symptoms
  • Expands the arsenal of preventive measures against RSV in a vulnerable age group
  • Marks a significant milestone in Pfizer's RSV vaccine program

summary download arrow Download Free Sample

Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

27.1%

Largest Market

North America

Fastest Growing Market

N/A

Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market Dynamics

The high disease burden of RSV, especially in vulnerable populations, is a primary driver for market growth. RSV is responsible for substantial healthcare costs, with annual US hospitalization costs for infants estimated at $650 million. The potential for vaccines and antibodies to significantly reduce this burden is fueling investment and research. Advancements in vaccine technology, including mRNA platforms and structure-based antigen design, have overcome previous obstacles in RSV vaccine development. These innovations allow for more precise targeting of RSV's fusion (F) protein, a key component for viral entry into host cells. The market is also benefiting from increased government and private funding for vaccine development, particularly following the COVID-19 pandemic. However, challenges remain, including the need to develop safe and effective products for diverse age groups and the complexity of conducting large-scale clinical trials in pediatric populations. Regulatory scrutiny is high due to historical incidents of vaccine-enhanced disease in RSV vaccine trials, necessitating extensive safety data. This scrutiny, while ensuring product safety, can extend development timelines and increase costs.

Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market CAGR

27.1%

By Product Type

  • Vaccines
  • Monoclonal Antibodies

By Target Population

  • Infants
  • Older Adults
  • Pregnant Women

By Clinical Trial Phase

  • Phase I
  • Phase II
  • Phase III

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market is expected to grow at a CAGR of 27.1% from 2024 to 2030.

The Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market is segmented based on Product Type, Target Population, Clinical Trial Phase, and Geography.

The leading players in the global Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market are GSK, Pfizer, Moderna, AstraZeneca, Sanofi, Janssen (Johnson & Johnson), Novavax, Bavarian Nordic, Merck, and Codagenix.

Historic years considered for the market study are 2019-2022, 2023 is considered as the base year for market estimation, and Seven years forecast is presented from 2024 – 2030.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market  Introduction 
2.1.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market   - Taxonomy
2.2.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market   - Definitions
2.2.1. Product
2.2.2.Target Population
2.2.3.Clinical Trial Phase
2.2.4.Region
3.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market  Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market  Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market   By  Product, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Vaccines
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Monoclonal Antibodies
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market   By Target Population, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Infants
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Older Adults
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Pregnant Women
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market   By Clinical Trial Phase, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Phase I
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Phase II
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Phase III
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market   By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market  ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Vaccines
9.1.2.Monoclonal Antibodies
9.2.  Target Population Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Infants
9.2.2.Older Adults
9.2.3.Pregnant Women
9.3.  Clinical Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Phase I
9.3.2.Phase II
9.3.3.Phase III
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market  ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1.  Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Vaccines
10.1.2.Monoclonal Antibodies
10.2.  Target Population Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Infants
10.2.2.Older Adults
10.2.3.Pregnant Women
10.3.  Clinical Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Phase I
10.3.2.Phase II
10.3.3.Phase III
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market  ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1.  Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Vaccines
11.1.2.Monoclonal Antibodies
11.2.  Target Population Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Infants
11.2.2.Older Adults
11.2.3.Pregnant Women
11.3.  Clinical Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Phase I
11.3.2.Phase II
11.3.3.Phase III
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market  ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1.  Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Vaccines
12.1.2.Monoclonal Antibodies
12.2.  Target Population Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Infants
12.2.2.Older Adults
12.2.3.Pregnant Women
12.3.  Clinical Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Phase I
12.3.2.Phase II
12.3.3.Phase III
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market  ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1.  Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Vaccines
13.1.2.Monoclonal Antibodies
13.2.  Target Population Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Infants
13.2.2.Older Adults
13.2.3.Pregnant Women
13.3.  Clinical Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Phase I
13.3.2.Phase II
13.3.3.Phase III
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.GSK
14.2.2.Pfizer
14.2.3.Moderna
14.2.4.AstraZeneca
14.2.5.Sanofi
14.2.6.Janssen (Johnson & Johnson)
14.2.7.Novavax
14.2.8.Bavarian Nordic
14.2.9.Merck
14.2.10.Codagenix
14.2.11.Meissa Vaccines
14.2.12.Icosavax
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • GSK
  • Pfizer
  • Moderna
  • AstraZeneca
  • Sanofi
  • Janssen (Johnson & Johnson)
  • Novavax
  • Bavarian Nordic
  • Merck
  • Codagenix
  • Meissa Vaccines
  • Icosavax

Related Industry Reports

Antibody Combination Therapy Market

Antibody Fragments Market

Anesthesia And Respiratory Devices Market

Global Respiratory Inhaler Devices Market